Saltar al contenido
PivotalWire
Martes 13 oct 2026SEC · NASDAQ biomédico

Portada›Jueves 16 de octubre de 2025

Biomédicas del NASDAQ ante la SEC, jueves 16 de octubre de 2025

Los 34 documentos que 29 empresas del sector presentaron ante la SEC ese día, agrupados por tipo y con el enlace al original en EDGAR.

·

El día, bloque a bloque

¿Lo quieres en tu correo cada mañana, y solo de tus empresas? Crear una cuenta.

Va en color lo que cambia el capital o avisa de un riesgo: las emisiones con precio (424B1, 424B2, 424B4 y 424B5), los 8-K con item 1.02, 1.03, 2.04, 3.01, 3.02 y 4.02, y cualquier documento en el que haya aparecido una frase vigilada, que va citada debajo. Lo demás va en tinta normal. Una cita marcada «por primera vez» es una frase que no estaba en el informe previo del mismo tipo de esa empresa. La etiqueta del formulario lleva a su explicación.

Emisiones y dilución

  1. AKTXAkari Therapeutics Plc424B5Nueva emisión de acciones con precioEDGAR
  2. CCCCC4 Therapeutics, Inc.424B5Nueva emisión de acciones con precioEDGAR
  3. DWTXDogwood Therapeutics, Inc.S-3/ACapacidad de emisión registrada (enmienda)EDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing. The report of Forvis Mazars, LLP contains an explanatory paragraph regarding substantial doubt about the Company's ability to continue as a going concern. LIMITATION ON LIABILITY AND DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION OF SECURITIES ACT LIABILITIES Our certificate of incorporation and bylaws provide that we will indemnify our directors…
  4. ELABPMGC Holdings Inc.S-1Capacidad de emisión registradaEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…containing a microorganism transformed with a vector expressing myostatin and activin A on the cell surface as an active ingredient Going Concern As of December 31, 2024, management has determined there is substantial doubt about the Company’s ability to continue as a going concern. The Company may need to obtain funds to support its working capital, the methods of which include, without limitation, the following: ● this offering; ● other available sources of financing (including…
    En el documentoContrasplit de accionestexto original ▸…Skincare. On November 13, 2024, PMGC Capital LLC (“PMGC Capital”) was incorporated under the laws of the state of Nevada. PMGC is the sole shareholder of PMGC Capital. On November 27, 2024, the Company completed a reverse stock split on a ratio of two hundred old shares of common stock for every one new post reverse split common share. In addition, on March 10, 2025, the Company completed a second reverse stock split on a ratio of…
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸…does not purport to be complete and is subject to and are qualified in their entirety by a copy of the Northstrive Secondment Agreement, filed herein as Exhibit 10.32. 45 ● On April 24, 2025, the Company entered into an At-The-Market Issuance Sales Agreement (the “Sales Agreement”) with Univest Securities, LLC (“Univest”), under which the Company may issue and sell from time to time, shares of its common stock, par value $0.0001 per share, having an aggregate…
  5. LXEOLexeo Therapeutics, Inc.424B5Nueva emisión de acciones con precioEDGAR
  6. ONCOOnconetix, Inc.S-1Capacidad de emisión registradaEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…assurance that additional capital will be available to us on acceptable terms, or at all, or that we will ever generate revenue sufficient to provide self-sustaining cash flows. These circumstances raise substantial doubt about our ability to continue as a going concern. The condensed consolidated financial statements incorporated by reference in this prospectus do not include any adjustment that might be necessary if the Company is unable to continue as a going concern…
    En el documentoContrasplit de accionestexto original ▸…in this prospectus do not include any adjustment that might be necessary if the Company is unable to continue as a going concern. Recent Developments Reverse Stock Split On June 13, 2025, the Company effected a reverse stock split of all shares of its issued and outstanding Common Stock at a ratio of one-for-eighty-five (1:85). The Company accounted for the reverse stock split on a retrospective basis pursuant to Accounting Standards…
  7. PRAXPraxis Precision Medicines, Inc.424B5Nueva emisión de acciones con precioEDGAR

Participaciones y control

  1. CLYMClimb Bio, Inc.SC 13D/ACambio en participación significativaEDGAR
  2. CYPHCYPHERPUNK TECHNOLOGIES INC.SC 13DCambio en participación significativaEDGAR
  3. HUMAHumacyte, Inc.SC 13D/ACambio en participación significativaEDGAR
  4. KROSKeros Therapeutics, Inc.SC 13D/ACambio en participación significativaEDGAR
  5. RNAZTranscode Therapeutics, Inc.SC 13DCambio en participación significativaEDGAR
  6. VORVor Biopharma Inc.SC 13D/ACambio en participación significativaEDGAR

Informes y hechos relevantes

  1. AKTXAkari Therapeutics Plc8-KVenta de acciones no registrada (colocación privada)EDGAR
  2. HCWBHCW Biologics Inc.8-KAviso de incumplimiento de cotizaciónEDGAR
  3. LNAILunai Bioworks Inc.8-KAviso de incumplimiento de cotizaciónEDGAR
  4. PALIPALISADE BIO, INC.8-KOtros hechos relevantesEDGAR
    En el documentoAviso de incumplimiento de las reglas de cotizacióntexto original ▸…Nasdaq rules, the Company was provided an initial period of 180 calendar days, or until October 27, 2025, to regain compliance with the Minimum Bid Price Requirement. On October 15, 2025, the Company received a minimum bid price compliance letter from the Staff confirming the Company has regained compliance with Listing Rule 5550(a)(2), and that the matter is now closed. There can be no assurance, however, that the Company will…
  5. SCNXScienture Holdings, Inc.8-KFin de acuerdo materialEDGAR
  6. BCTXBriaCell Therapeutics Corp.10-KInforme anualEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…in the fiscal years ended 2025 and 2024, respectively, and an accumulated deficit of $111,755,564 and $85,443,697 as of July 31, 2025 and July 31, 2024, respectively. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to generate positive cash flows from operations and to secure additional sources of equity and/or debt financing. Despite the…
    En el documentoContrasplit de accionestexto original ▸…compliance with the minimum bid price requirement. Under the Nasdaq Excessive Reverse Stock Split Rule, if a company’s common shares fail to meet the minimum bid price requirement and the company has effected a reverse stock split within the prior one-year period, it will not be eligible for any compliance period to address a bid price deficiency. Accordingly, if our common shares fall out of compliance with the minimum bid requirement…
  7. BIAFbioAffinity Technologies, Inc.8-KOtros hechos relevantesEDGAR
  8. CCCCC4 Therapeutics, Inc.8-KNuevo acuerdo materialEDGAR
  9. CCCCC4 Therapeutics, Inc.8-KOtros hechos relevantesEDGAR
  10. DNTHDianthus Therapeutics, Inc. /DE/8-KNuevo acuerdo materialEDGAR
    En el documentoAcuerdo de licencia o colaboracióntexto original ▸…protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Consideration Under the terms of the License Agreement, the Company will pay Leads up to $38 million, comprised of $30 million in upfront and near-term milestone payments plus an additional $8 million milestone, payable in cash or the Company's common stock at the Company's election, upon the initiation of a Dianthus-led Phase 1 study,…
  11. INMInMed Pharmaceuticals Inc.8-KCambio en el consejo o la direcciónEDGAR
  12. KURAKura Oncology, Inc.8-KOtros hechos relevantesEDGAR
  13. MIRAMIRA PHARMACEUTICALS, INC.8-KOtros hechos relevantesEDGAR
  14. PLURPluri Inc.8-KCambio en el consejo o la direcciónEDGAR
  15. PRAXPraxis Precision Medicines, Inc.8-KOtros hechos relevantesEDGAR
  16. PULMPulmatrix, Inc.8-KResultadosEDGAR
  17. PULMPulmatrix, Inc.10-QInforme trimestralEDGAR
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸…30, 2025 December 31, 2024 Legal and patents $ 67 $ 11 Wages and incentives 37 38 Other 76 71 Total accrued expenses and other current liabilities $ 180 $ 120 8 5. Common Stock In May 2021, the Company entered into an At-The-Market Sales Agreement (the “Sales Agreement”) with H.C. Wainwright and Co., LLC (“HCW”) to act as the Company’s sales agent with respect to the issuance and sale of up to $20.0 million of the Company’s shares of common stock…
  18. TLPHTALPHERA, INC.8-KCambio en el consejo o la direcciónEDGAR
  19. TSHATaysha Gene Therapies, Inc.8-KOtros hechos relevantesEDGAR
    En el documentoDesignación de terapia innovadora (breakthrough)texto original ▸…syndrome program enables Taysha to focus on driving its long-term value with full strategic flexibility and optionality TSHA-102 has demonstrated compelling Part A REVEAL Phase 1/2 safety and efficacy data, received FDA Breakthrough Therapy designation and is advancing with a clear path to potential registration Dosing of the first patient in the REVEAL pivotal trial is scheduled this quarter Dallas – October 16, 2025 – Taysha Gene Therapies, Inc.…
  20. XENEXenon Pharmaceuticals Inc.8-KCambio en el consejo o la direcciónEDGAR
    En el documentoCambio en la dirección de la empresatexto original ▸…Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 16, 2025, Xenon Pharmaceuticals Inc. (the “Company”) announced that Thomas (Tucker) Kelly has been appointed to serve as the Company’s Chief Financial Officer, effective October 15, 2025. In connection with his appointment, Mr. Kelly will serve as the Company’s principal financial officer and principal accounting officer. Mr. Kelly, age 54, previously served…
  21. ZLABZai Lab Ltd8-KNuevo acuerdo materialEDGAR

·

Esto mismo, cada mañana y solo de tus empresas. Sigue a las que te interesen y recibe en tu correo lo que presenten ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.

Esto no son recomendaciones de inversión. Son hechos públicos verificables en su fuente. Lee siempre el documento original antes de decidir nada. Aviso legal.